Forbion Growth Management B.V., 10% Owner at NewAmsterdam Pharma Co N.V. (NAMS), sold 924,576 shares at $26.15 ($23.5M) on 2024-12-10, disclosed to the SEC on 2024-12-12.
Scheduled sale ($23.5M) by 10% Owner under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $25.22 | 259,739 | $6.6M | 27.9% |
| 2 | $25.22 | 259,739 | $6.6M | 27.9% |
| 3 | $26.15 | 48,511 | $1.3M | 5.4% |
| 4 | $26.15 | 48,511 | $1.3M | 5.4% |
| 5 | $25.26 | 130,561 | $3.3M | 14.0% |
| 6 | $25.26 | 130,561 |
| $3.3M |
| 14.0% |
| 7 | $26.41 | 18,583 | $491K | 2.1% |
| 8 | $26.41 | 18,583 | $491K | 2.1% |
| 9 | $27.11 | 4,894 | $133K | 0.6% |
| 10 | $27.11 | 4,894 | $133K | 0.6% |
| Total | $25.40 avg | 924,576 | $23.5M | 100% |